Voyager’s Tau-Targeted Gene Therapy VY1706 and Anti-Tau Antibody VY7523 for Alzheimer’s Disease to Be Featured in Poster Presentations at CTAD 2026
Voyager Therapeutics announced two poster presentations at the 19th Clinical Trials on Alzheimer's Disease (CTAD) Conference in Boston, November 16-19, 2026. The posters will cover the first-in-human study design of VY1706, a BBB-penetrant tau-lowering gene therapy, and baseline data from a multiple ascending dose study of the anti-tau antibody VY7523, both in early Alzheimer's disease.
Key figures
- Drug Name
- VY1706; VY7523
- Phase Of Trial
- Phase I & IIa
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.